Amneal Pharmaceuticals, Inc.
AMRXUS売上高
$3.0B
百万USD
営業利益
$394M
百万USD
純利益
$72M
百万USD
ROE
-101.8%
最新FY
EPS
$0.22
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $493M | $13M | $0.04 |
| FY2021 | Q2 | $535M | $30M | $0.10 |
| FY2021 | Q3 | $529M | $-8M | $-0.03 |
| FY2021 | FY | $2.1B | $13M | $0.07 |
| FY2022 | Q1 | $498M | $-9M | $-0.01 |
| FY2022 | Q2 | $559M | $-242M | $-0.80 |
| FY2022 | Q3 | $546M | $-8M | $-0.02 |
| FY2022 | FY | $2.2B | $-271M | $-0.86 |
| FY2023 | Q1 | $558M | $-16M | $-0.05 |
| FY2023 | Q2 | $599M | $22M | $0.08 |
| FY2023 | Q3 | $620M | $16M | $0.06 |
| FY2023 | FY | $2.4B | $-79M | $-0.48 |
| FY2024 | Q1 | $659M | $-92M | $-0.30 |
| FY2024 | Q2 | $702M | $6M | $0.02 |
| FY2024 | Q3 | $702M | $-0M | $0.00 |
| FY2024 | FY | $2.8B | - | $-0.38 |
| FY2025 | Q1 | $695M | $12M | $0.04 |
| FY2025 | Q2 | $725M | $22M | $0.07 |
| FY2025 | Q3 | $785M | $2M | $0.01 |
| FY2025 | FY | $3.0B | $72M | $0.22 |
| FY2026 | Q1 | $723M | $62M | $0.19 |
財務データ
| 指標 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | $1.7B | $1.6B | $2.0B | $2.1B | $2.2B | $2.4B | $2.8B | $3.0B |
| 営業利益 | - | $-20M | $-249M | $91M | $153M | $-95M | $204M | $249M | $394M |
| 純利益 | - | $-20M | $-362M | $91M | $13M | $-271M | $-79M | - | $72M |
| 総資産 | $0M | $4.4B | $3.7B | $4.0B | $3.9B | $3.8B | $3.5B | $3.5B | $3.7B |
| 純資産 | - | $896M | $347M | $345M | $367M | $184M | $20M | $-110M | $-71M |
| 自己資本 | $0M | $505M | $232M | $303M | $360M | $298M | $20M | $-109M | $-71M |
| 営業CF | - | $250M | $2M | $379M | $242M | $65M | $346M | $295M | $340M |
| EPS | - | - | - | $0.61 | $0.07 | $-0.86 | $-0.48 | $-0.38 | $0.22 |
| BPS | $0.00 | - | - | - | - | - | $0.06 | $-0.35 | $-0.23 |
| ROE | - | -3.9% | -156.0% | 30.0% | 3.7% | -90.7% | -400.7% | - | -101.8% |